Serum HER-2/ECD analysis in monitoring breast cancer patients

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 1, 2012, Pages 175-176

  Sørensen, Patricia Diana ^a,b   Madsen, Jonna Skov ^a,b   Brandslund, Ivan ^a,b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Breast cancer; HER 2; Metastases; Serum HER 2 ECD

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADVANCED CANCER; ANALYTIC METHOD; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FLUORESCENCE IN SITU HYBRIDIZATION; HEPATITIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LIVER CIRRHOSIS; LIVER METASTASIS; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; SURVIVAL RATE; TREATMENT RESPONSE;

BREAST NEOPLASMS; FEMALE; HUMANS; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2;

EID: 84857852411     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.722     Document Type: Letter

References (7)

1. Leyland-Jones B, Smith BR. Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls. Lancet Oncol 2011;12:286-95.
2. Mathelin C, Croce S, Rault S, Gharbi M, Eichler F, Gairard B, et al. Clinical usefulness of circulating ECD/HER-2 measurement for breast cancer patients' management. Presse Med 2011;40: 126-37. Epub 2010 Nov 11. Review. wIn French.x
3. Tse C, Lamy PJ. Clinical utility of serum human epidermal growth factor receptor 2 extracellular domain levels: stop the shilly-shally-it is time for a well-designed, large-scale prospective study. J Clin Oncol 2009;27:e286-7. Epub 2009 Nov 16.
4. Sørensen PD, Jakobsen EH, Langkjer ST, Bokmand S, Oestergaard B, Olsen DA, et al. Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting. Clin Chem Lab Med 2009;47:1117-23.
5. Fornier MN, Seidman AD, Schwartz MK, Ghani F, Thiel R, Norton L, et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and pacli-taxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 2005;16:234-9. (Pubitemid 40309302)
6. Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 2005;7:R436-43.
7. Ali SM, Carney WP, Esteva FJ, Fornier M, Harris L, Kostler WJ, et al. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer 2008;113:1294-301.